- ACA 125
- Anti-idiotype ovarian cancer vaccine
- MAb ACA 125
- Monoclonal Anti-idiotype Antibody ACA125
Mechanism of action
- A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity.
- With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation resulting in inhibition of tumor cell proliferation
Abagovomab has been developed by the pharmaceutical company Menarini.
A multicenter clinical trial, internationally known as MIMOSA is being studied. In this study, Abagovomab was administered as maintenance therapy after first line therapy with surgery and chemotherapy, as opposed to standard therapy with paclitaxel and carboplatin.
- Unfortunately, phase III of a trial looking at potential benefit of Abagavomab in patients treated with ovarian cancer showed no benefit in preventing a remission.
Ovarian cancer is an aggressive type of cancer with significant mortality. In spite of initially successful treatment with surgery and chemotherapy, which forces back the tumour "completely", i.e. into no longer visible residues, there is a relapse of the disease (recurrence) in more than half the women affected. In this window, after surgery and chemotherapy, ‘watch and wait’ abagovomab is potentially capable of deferring or even preventing the occurrence of the relapse.
- Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
- Clinical trials
- Menarini page about abagovomab
- Clinical trial MIMOSA